Compare Li Auto Inc (LI) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs Medpace Holdings Inc — how do they compare? Li Auto Inc trades at $12.17 (market cap $12.43B), while Medpace Holdings Inc trades at $530 (market cap $15.08B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals.
| LI | MEDP | |
|---|---|---|
Market Cap | $12.43B | $15.08B |
Sector | Consumer Cyclical | Technology |
52-Week High | $30.84 | $620.59 |
52-Week Low | $11.74 | $308.88 |
Enterprise Value | $1.34B | $14.55B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Li Auto (LI) trades at $12.21, down 1.45% on the day, amid a bearish technical signal and mixed earnings history. The company reported a net income margin of -1.66% for 2025, with revenue declining to $112.31 billion from $144.5 billion in 2024. Recent news includes the launch of new SUV models like the Li L6 in July 2026, aiming to bolster sales in a competitive EV market. Cash flow trends show operational challenges, with negative operating cash flow of $8.61 billion in 2025, though 2026 projections indicate a potential recovery.
Outlook remains cautious due to profitability concerns and intense competition, but analyst consensus suggests upside with a $14.80 price target. Risks include execution hurdles and macroeconomic pressures, yet institutional sentiment leans neutral with 50% hold ratings. Investors should weigh near-term volatility against long-term growth potential in China's EV sector.
MEDP trades at $527.93, down 1.82% on the day, with a neutral technical signal and mixed oscillators. The stock shows strong profitability with a 17.19% net margin and 77.25% ROE, though valuations are elevated with a P/E of 33.22. Recent quarters have consistently beaten EPS estimates, but a class action lawsuit filed in June 2026 adds uncertainty. Revenue is projected to grow to $2.7B in 2026, while cash flow trends improve from negative to positive net cash flow.
The outlook is cautious due to high valuation and legal overhangs, but fundamental strength in earnings and backlog quality provides support. Analyst consensus is mixed with a $497 price target below current levels, indicating limited near-term upside. Key risks include lawsuit outcomes and competitive pressures in the CRO sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
